

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome	Andrea Gori
Telefono	02 55034763
Cell.	333 8109128
E-mail	andrea.gori@unimi.it
Nazionalità	Italiana
Luogo e Data di nascita	Bergamo, 19.03.1963

ESPERIENZA LAVORATIVA

dal 2018 ad oggi	Professore Ordinario Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica dei Trapianti
dal 2018 ad oggi	Direttore UOC Malattie Infettive, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
dal 2014 al 2018	Professore Straordinario Università degli Studi Milano Bicocca, Dipartimento di Scienze della Salute
dal 2007 al 2018	Direttore dell'Unità Operativa Complessa di Malattie Infettive, ASST-Monza Ospedale "San Gerardo", Monza (MB)
dal 2006 al 2007	Dirigente Medico di I livello, Responsabile Ricerca Clinica, Clinica di Malattie Infettive e Tropicali (Direttore: Prof. A. d'Arminio Monforte), Dipartimento di Medicina Interna (Direttore Prof. M. Podda), Università di Milano
dal 1995 al 2005	Dirigente Medico di I livello, Clinica di Malattie Infettive e Tropicali, Ospedale "Luigi Sacco", Milano. (Direttore Prof. M. Moroni)
dal 1991 al 1993	Borsista, Scuola di Specialità in Malattie Infettive, Istituto di Malattie Infettive e Tropicali, Università di Milano (Direttore: Prof. M. Moroni)

ISTRUZIONE E FORMAZIONE

1995	Specializzazione in Malattie Infettive, Università degli Studi di Milano (Direttore: Prof. M. Moroni)
1993-1994	Researcher Fellow, Department of Mycobacteriology and Molecular Microbiology, National Institute of Public Health and Environmental Protection, RIVM, Bilthoven, The Netherlands (Direttore: J.D.A. van Embden)
1991-1992	Researcher Fellow, Clinique des Maladies Infectieuses, Hopital Universitaire Saint-Pierre, Université Libre de Bruxelles, Bruxelles, Belgio (Direttore: Prof. N. Clumeck)
1991-1992	Researcher Fellow, Institute de Microbiologie, Hopital Académique Erasme, Université Libre de Bruxelles, Bruxelles, Belgio (Direttore: Prof. M.J. Struelens)
1991-1992	Borsista presso Università degli Studi di Milano, Attività di Perfezionamento all'Estero presso Istituzioni Universitarie Internazionali
1991	Laurea in Medicina e Chirurgia, <i>Università degli Studi di Milano (Direttore: Prof. M. Moroni)</i>

DIDATTICA

dal 2018 ad oggi	Professore Ordinario Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica dei Trapianti
dal 2007 al 2018	Professore a contratto per il Corso di Malattie Infettive, Semeiotica 2-3; Laurea in Medicina e Chirurgia presso l'Università Milano-Bicocca
dal 2007 al 2018	Professore a contratto per il Corso di Malattie Infettive; Laurea in Odontoiatria presso l'Università degli Studi di Milano-Bicocca
dal 2007 al 2018	Professore a contratto Scuola di Specializzazione in Medicina Interna, Medicina d'Urgenza, Pediatria, Pneumologia ed Ematologia presso l'Università Milano-Bicocca
dal 2005 al 2006	Professore a contratto per il Corso di Malattie Infettive; Laurea in Medicina e Chirurgia presso l'Università di Milano, Polo "San Paolo"
Dal 2002 al 2005	Professore a contratto per il Corso di Malattie Infettive; Laurea in Medicina e Chirurgia presso l'Università di Milano, Polo "Luigi Sacco"

PROGETTI DI RICERCA

Dal 2010 ad oggi	Membro dello Steering Committee delle "Linee guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1"
Dal 2008 ad oggi	Titolare del progetto "Diagnosi avanzata e modelli di gestione della malattia tubercolare". Ricerca Finanziata, Ministero della Sanità
Dal 2008 ad oggi	Coordinatore del progetto: "Molecular epidemiology of drug resistant strains in selected metropolitan settings in Western and Eastern Europe. Pan-European network for the study and clinical management of drug resistant tuberculosis. European Union - 7 th Framework Programme
Dal 2006 ad oggi	Membro del Consiglio Direttivo StopTB Italia, Partnership StopTB WHO
Dal 2005 ad oggi	Esperto per il WHO sulla trasmissione e controllo della malattia tubercolare e della infezione HIV/TB
Dal 2003 ad oggi	Titolare del Progetto di ricerca sulle modificazione della risposta immunitaria nei pazienti HIV-positivi. Fondazione "Ermenegildo Zegna", Progetto AIDS
Dal 2002 ad oggi	Coordinatore in qualità di Principal Investigator per clinical trials multicentrici nazionali ed internazionali (fase I, II, III) per lo sviluppo di nuovi farmaci immunomodulanti e vaccini per la cura dell'infezione da HIV
Dal 2006 al 2008	Coordinatore nazionale del gruppo di lavoro tubercolosi: Società Italiana Malattie Infettive
Dal 2002 al 2008	Membro della Commissione Regionale Tubercolosi, Regione Lombardia
Dal 2005 al 2007	Responsabile del Laboratorio di epidemiologia molecolare per l'Italian Supranational Reference Center, Istituto Superiore di Sanità all'interno del European Surveillance of Multidrug resistant TB, Euro TB/RIVM
Dal 2003 al 2007	Co-titolare del Progetto "Materiali microstrutturati per la coltura di cellule staminali emopoietiche per la terapia cellulare di neoplasie e immunodepressione", Progetto di Finanziamento alla Ricerca, Fondazione Cariplo
Dal 2002 al 2004	Titolare di un Progetto di ricerca "Ruolo della risposta immune nelle infezioni del paziente trapiantato", Ricerca Finanziata, Ministero della Sanità
Dal 1998 al 2001	Titolare di Progetti di ricerca inerenti l'immunopatogenesi e lo studio di nuovi approcci terapeutici nell'infezione tubercolare finanziati dall'Istituto Superiore di Sanità e dal Ministero della Salute
Dal 1998 al 2001	Titolare di Progetti di ricerca inerenti l'immunopatogenesi e lo studio di terapie immunomodulanti nell'infezione da HIV finanziati dall'Istituto Superiore di Sanità, Progetto Nazionale AIDS
Dal 1996 al 2002	Responsabile del Progetto di ricerca "Trasmissione e controllo della malattia tubercolare, "Progetto Nazionale tubercolosi", Istituto Superiore di Sanità
Dal 1996 al 2002	Responsabile italiano del Progetto Europeo "Molecular Epidemiology of Tuberculosis in Europe", Concerted Action, Biomed 2, EU (Responsabili: J.D.A. van Embden e P. Small) finanziato dalla Comunità Europea
Dal 1996 al 1997	Responsabile italiano del Progetto Europeo "Multidrug Resistant Tuberculosis in Europe", Concerted Action, Biomed 2, EU (Responsabile: H. Rinder) finanziato dalla Comunità Europea

PREMI E RICONOSCIMENTI

2014	Abilitazione Nazionale per Professore di I ^a e II ^a fascia
2013	Vincitore <i>Gilead Fellowship</i> Program come miglior progetto indipendente su HIV
2012	Vincitore <i>Gilead Fellowship</i> Program come miglior progetto indipendente su HIV
2009	Ha ricevuto la "Rosa Camuna". Onorificenza in campo sanitario della Regione Lombardia
2008	Rappresentante per il Ministero degli Affari Esteri: StopTB Partnership International Coordinating Board, StopTB Partnership, WHO
1995	Young investigator award winner, American College of Chest Physicians, 1995. New York, USA
1992	Premio "Fabrizio Rocca", Associazione Nazionale per la Lotta contro l'AIDS

PUBBLICAZIONI

Le principali aree di ricerca in cui si è impegnato sono:

Infezione da HIV

Infezione tubercolare

Infezione nell'ospite immunocompromesso

Ruolo del sistema immunitario nelle infezioni HIV/TB

Patogenesi dell'infezione da HIV e dei meccanismi di Immunoricostruzione e omeostasi T-linfocitaria in corso di infezione da HIV

Coautore dalla V^a alla 8^a edizione del volume monografico "Malattie Infettive" Moroni, Esposito, de Lalla. Edito da Masson

Coautore del volume monografico "HIV Medicine (www.HIVMedicine.com)" medical textbook. Hoffmann, Rockstroh, Kamps 15^{ma} e 16^{ma} Edizione. Flying Publisher

Attività di reviewer per: New England Journal of Medicine, Lancet, AIDS, Clinical Infection Diseases, Journal of Infection Diseases, Journal of Clinical Microbiology, European Respiratory Journal, Antiviral Therapy, Journal of AIDS

Autore di più di 250 pubblicazioni su riviste internazionali peer reviewed

IF Totale = 1252,116

IF (ultimi 5 anni: 2017-2013) = 586,826

Citation index: 5307

h-index: 37 (google scholar)

CAPACITÀ E COMPETENZE

PERSONALI

PRIMA LINGUA

Italiano

ALTRE LINGUE

Inglese

Eccellente

• Capacità di lettura

Eccellente

• Capacità di scrittura

Eccellente

• Capacità di espressione orale

Francese

Eccellente

• Capacità di lettura

Eccellente

• Capacità di scrittura

Eccellente

• Capacità di espressione orale

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

ECCELLENTE

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

ECCELLENTE

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

ECCELLENTE

ALLEGATI

SI ALLEGA ELENCO DELLE PUBBLICAZIONI SCIENTIFICHE

ELENCO DELLE PUBBLICAZIONI SCIENTIFICHE

1. Biffi S, Di Bella S, Scaravilli V, Peri AM, Grasselli G, Alagna L, Pesenti A, **Gori A**. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. **Int J Antimicrob Agents.** 2017 May 18. pii: S0924-8579(17)30161-9. (IF: 4.097)
2. d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, **Gori A**, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and Hepalcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. **PLoS One.** 2017 May 17;12(5):e0177402. (IF: 3.057)
3. Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. **New Microbiol.** 2017 Apr;40(2):86-98. (IF: 1.629)
4. Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA \leq 50 cp/mL. **Infection.** 2017 May 5. doi: 10.1007/s15010-017-1018-z. (IF: 2.294)
5. Soria A, Fabbiani M, Lapadula G, **Gori A**. Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs. **Hepatology.** 2017 Mar 30. doi: 10.1002/hep.29181. (IF: 11.711)
6. Sironi M, Peri AM, Cagliani R, Forni D, Riva S, Biasin M, Clerici M, **Gori A**. TLR3 mutations in adult patients with Herpes Simplex virus and Varicella Zoster virus encephalitis. **J Infect Dis.** 2017 Mar 27. doi: 10.1093/infdis/jix166. (IF: 6.344)
7. Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, **Gori A**, Sighinolfi L, Pan A, Mazzini N, Torti C. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. **BMC Infect Dis.** 2017 Mar 15;17(1):212. (IF: 2.690)
8. Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, **Gori A**, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Disegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. **PLoS One.** 2017 Feb 28;12(2):e0172159. (IF: 3.057)
9. Soria A, Alteri C, Scarlatti G, Bertoli A, Tolazzi M, Balestra E, Bellocchi MC, Continenza F, Carioti L, Biasin M, Trabattoni D, Bandera A, Ceccherini-Silberstein F, Perno CF, **Gori A**. Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report. **Clin Infect Dis.** 2017 Mar 15;64(6):810-813. (IF: 8.736)
10. Puoti M, Lorenzini P, Cozzi-Lepri A, **Gori A**, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. **Clin Microbiol Infect.** 2017 Apr;23(4):267.e1-267.e4. (IF: 4.575)
11. Bandera A, Colella E, Rizzardini G, **Gori A**, Clerici M. Strategies to limit immune-activation in HIV patients. **Expert Rev Anti Infect Ther.** 2017 Jan;15(1):43-54. (IF: 3.461)
12. Andreoni M, Teti E, Antinori A, Milazzo L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, **Gori A**, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirianni A, Pennica A, Pasquazzi C, Segala D, Sarmati L; SIMIT (Società Italiana di Malattie Infettive e Tropicali). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. **Clin Infect Dis.** 2016 Dec 22. pii: ciw846. (IF: 8.736)

13. Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, Marruchella A, **Gori A**, Blasi F, Codecasa L, Pesci A, Chalmers JD, Loebinger MR, Aliberti S. Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis.
Int J Mol Sci. 2016 Nov 16;17(11). pii: E1913. (IF: 3.257)
14. Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P, d'Arminio Monforte A, **Gori A**; ICONA Foundation Study Group. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
PLoS One. 2016 Oct 7;11(10):e0160761. (IF: 3.057)
15. Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondì A, Costarelli S, Valsecchi MG, Torti C, **Gori A**; Italian MASTER cohort. Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
PLoS One. 2016 Sep 15;11(9):e0162320. (IF: 3.057)
16. Squillace N, Galli L, Bandera A, Castagna A, Madeddu G, Caramello P, Antinori A, Cattelan A, Maggiolo F, Cingolani A, **Gori A**, Monforte Ad; ICONA Foundation Study Group. High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort.
Medicine. 2016 Sep;95(36):e4434. (IF: 2.133)
17. Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondì A, Galizzi N, Maillard M, **Gori A**, Cauda R, De Luca A, Gianotti N. Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
J Infect. 2016 Dec;73(6):619-623. (IF: 4.382)
18. Raffetti E, Postorino MC, Castelli F, Casari S, Castelnuovo F, Maggiolo F, Di Filippo E, D'Avino A, **Gori A**, Ladisa N, Di Pietro M, Sighinolfi L, Zacchi F, Torti C. The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort.
BMC Public Health. 2016 Aug 25;16(1):878. (IF: 2.209)
19. Quiros-Roldan E, Raffetti E, Castelli F, Focà E, Castelnuovo F, Di Pietro M, Gagliardini R, **Gori A**, Saracino A, Fornabaio C, Sighinolfi L, Di Filippo E, Maggiolo F, Donato F. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
J Antimicrob Chemother. 2016 Dec;71(12):3519-3527. (IF: 4.919)
20. Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, **Gori A**, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Medicine. 2016 Jul;95(29):e4091. (IF: 2.133 – Cites: 1)
21. Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, **Gori A**, d'Arminio Monforte A; Icona Foundation Study Group. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.
J Antimicrob Chemother. 2016 Sep;71(9):2663-9. (IF: 4.919 – Cites: 3)
22. Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S, Saracino A, Di Pietro M, **Gori A**. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1511-20. (IF: 2.857)
23. Columpsi P, Sacchi P, Zuccaro V, Cima S, Sarda C, Mariani M, **Gori A**, Bruno R. Beyond the gut bacterial microbiota: The gut virome.
J Med Virol. 2016 Sep;88(9):1467-72. (IF: 1.998 – Cites: 3)
24. Di Bella S, **Gori A**. The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options.
Int J Antimicrob Agents. 2016 Mar;47(3):243-4. (IF: 4.097)

25. Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, **Gori A**, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Discontinuation of initial Antiretroviral therapy in clinical practice: moving toward individualized therapy. **J Acquir Immune Defic Syndr.** 2016 Mar 1;71(3):263-71. (IF: 3.806 – Cites: 8)
26. Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. **Lancet HIV.** 2016 Jan;3(1):e23-32. (IF: 8.364)
27. Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. **Clin Microbiol Infect.** 2016 Mar;22(3):288.e1-8. (IF: 4.575)
28. Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. **HIV Med.** 2016 Apr;17(4):255-68. (IF: 3.341)
29. Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. **PLoS One.** 2015 Dec 7;10(12):e0140877. (IF: 3.057)
30. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, **Gori A**, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXtAim Project. **New Microbiol.** 2015 Oct;38(4):443-90. (IF: 1.629 – Cites: 8)
31. Foresti S, Di Bella S, Rovelli A, Sala A, Verna M, Bisi L, Nisii C, **Gori A**. Tigecycline Lock Therapy for Catheter-Related Bloodstream Infection Caused by KPC-Producing Klebsiella pneumoniae in Two Pediatric Hematological Patients. **Antimicrob Agents Chemother.** 2015 Dec;59(12):7919-20. (IF: 4.415)
32. Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, **Gori A**, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G. Cohort profile: standardized management of antiretroviral therapy cohort (MASTER cohort). **Int J Epidemiol.** 2015 Oct 7. pii: dyv192. (IF: 7.522 – Cites: 9)
33. Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, Cingolani A, Lichtner M, Antinori A, **Gori A**, d'Arminio Monforte A; Icona Foundation Study Group. CD4/CD8 ratio normalization and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. **Lancet HIV.** 2015 Mar;2(3):e98-106. (IF: 8.364 – Cites: 45)
34. Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. **New Microbiol.** 2015 Jul;38(3):299-328. (IF: 1.629)
35. **Gori A**, Doroana M, Chernova O, Rockstroh JK, Banhegyi D, Bergin C, Verucchi G, Liu C, DeMasi R, Hadacek B, Nelson M. Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.

J Infect. 2015 Dec;71(6):675-82. (IF: 4.382)

36. Tavio M, Vivarelli M, Menzo S, Gori A, Grossi PA, Marigliano A. Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation.
Liver Transpl. 2015 Oct;21(10):1327-9. (IF: 3.951 – Cites: 4)
37. Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort. Risk of severe non-AIDS events is increased among patients unable to increase their CD4+ T-cell counts >200+/mcl despite effective HAART.
PLoS One. 2015 May 28;10(5):e0124741. (IF: 3.057 – Cites: 8)
38. Bonaiti G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S. Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis.
Biomed Res Int. 2015;2015:197950. (IF: 3.77 – Cites: 16)
39. Antinori A, Andreoni M, Perno CF, Lazzarin A; HEFFICON Study Group. HEFFICON: HIV Effectiveness Italian Conference.
New Microbiol. 2015 Apr;38(2):149-84. (IF: 1.629)
40. Cingolani A, Zona S, Girardi E, Cozzi-Lepri A, Monno L, Quiros Roldan E, Guaraldi G, Antinori A, D'Arminio Monforte A, Marcotullio S; Community-Oriented Study Group of the Icona Foundation Study Group. Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.
HIV Med. 2015 Aug;16(7):412-20. (IF: 3.341)
41. Soria A, Limonta S, Leone S, Muscatello A, Squillace N, Bandera A, Gori A. Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy.
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e37-40. (IF: 3.806 – Cites: 4)
42. Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.
PLoS One. 2015 May 1;10(5):e0124252. (IF: 3.057 – Cites: 1)
43. Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
Retrovirology. 2015 Apr 29;12:33. (IF: 3.989 – Cites: 24)
44. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
PLoS Med. 2015 Mar 31;12(3):e1001809. (IF: 13.585)
45. Bandera A, Mangioni D, Incontri A, Perseghin P, Gori A. Characterization of Immune Failure by Monocyte Activation Phenotypes in HIV-Infected Patients Receiving Antiretroviral Therapy.
J Infect Dis. 2015 Sep 1;212(5):839-41. (IF: 6.344)
46. Lapadula G, Gori A. Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1.
Ann Intern Med. 2015 Mar 17;162(6):461. (IF: 16.593)
47. Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D:A:D study.
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. (IF: 3.806)
48. Schioldi C, Carugati M, Zanini F, Bandera A, Di Nardo Stuppino S, Monge E, Morosi M, Gori A, Matteelli A, Codecasa L, Franzetti F. Exogenous reinfection of tuberculosis in a low-burden area.

Infection. 2015 Dec;43(6):647-53. (IF: 2.294 – Cites: 1)

49. Maloberti A, Dozio D, Betelli M, Bandera A, Squillace N, **Gori A**, Castoldi G, Stella A, Mancina G, Giannattasio C. Brachial and central blood pressure in HIV-infected subjects. **Hypertens Res.** 2015 Jun;38(6):405-12. (IF: 3.208 – Cites: 5)
50. Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, Quiros-Roldan E, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, **Gori A**, Nasta P, Torti C; Italian MASTER Cohort. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. **J Acquir Immune Defic Syndr.** 2015 Jul 1;69(3):312-8. (IF: 3.806 – Cites: 11)
51. Soria A, Trabattoni D, Squillace N, Rainone V, Gnudi F, Clerici M, **Gori A**, Bandera A. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial. **PLoS One.** 2015 Feb 11;10(2):e0117118. (IF: 3.057 – Cites: 2)
52. Postorino MC, Prosperi M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C; MASTER Study Group. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort. **Clin Microbiol Infect.** 2015 Apr;21(4):386.e1-9. (IF: 4.575)
53. Camoni L, Raimondo M, Dorrucchi M, Regine V, Salfa MC, Suligo B; CARPHA Study Group. Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. **AIDS Res Hum Retroviruses.** 2015 Mar;31(3):282-7. (IF: 1.949)
54. Bertacchi D, Zucca F, Foresti S, Mangioni D, **Gori A**. Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. **Math Med Biol.** 2015 Dec;32(4):383-403. (IF: 1.846)
55. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. **J Infect Dis.** 2015 Jan 15;211(2):178-86. (IF: 6.344 – Cites 48)
56. Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, **Gori A**, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Antinori A, Monforte AD; ICONA Foundation Study. Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. **J Int AIDS Soc.** 2014 Nov 2;17(4 Suppl 3):19825. (IF: 5.090)
57. Cozzi-Lepri A, Lo Caputo S, Maggiolo F, Antinori A, Ammassari A, Marchetti G, Mastroianni C, **Gori A**, Di Perri G, Angarano G, Carbone A, Monforte Ad; ICONA Foundation Study. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. **J Int AIDS Soc.** 2014 Nov 2;17(4 Suppl 3):19775. (IF: 5.090)
58. Cozzi-Lepri A, Antinori A, Bonora S, Cingolani A, Cassola G, Angarano G, Vullo V, Mussini C, **Gori A**, Maggiolo F, Castagna A; d'Arminio Monforte on behalf of the ICONA Foundation Study, Antonella. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. **J Int AIDS Soc.** 2014 Nov 2;17(4 Suppl 3):19771. (IF: 5.090)
59. Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, **Gori A**, D'Arminio-Monforte A. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. **J Int AIDS Soc.** 2014 Nov 2;17(4 Suppl 3):19571. (IF: 5.090)
60. Leone S, Migliorino G, **Gori A**. Brain abscess. **N Engl J Med.** 2014 Oct 30;371(18):1756. (IF: 55.873)

61. d'Arminio Monforte A, Galli L, Lo Caputo S, Lichtner M, Pinnetti C, Bobbio N, Francisci D, Costantini A, Cingolani A, Castelli F, Girardi E, Castagna A; ICONA Foundation Study Group. Pregnancy outcomes among ART-naïve and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013.
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):258-67. (IF: 4.556)
62. Mangioni D, Soria A, Brighina L, Bandera A, Ferrarese C, Gori A. A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α .
BMC Pharmacol Toxicol. 2014 Sep 30;15:56. (IF: 2.030 – Cites: 5)
63. Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, Squillace N, De Grandi C, Gori A, Bandera A. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?
Clin Infect Dis. 2014 Dec 1;59(11):1655-6. (IF: 8.886 – Cites: 3)
64. Di Biagio A, Nicolini LA, Lorenzini P, Puoti M, Antinori A, Cozzi-Lepri A, Gori A, Vecchiet J, Mussini C, Andreoni M, Viscoli C, d'Arminio Monforte A, For The Icona Foundation Study Group. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
HIV Clin Trials. 2014 Jul-Aug;15(4):151-60. (IF: 2.629 – Cites: 4)
65. Sironi M, Cagliani R, Pontremoli C, Rossi M, Migliorino G, Clerici M, Gori A. The CCR5 Δ 32 allele is not a major predisposing factor for severe H1N1pdm09 infection.
BMC Res Notes. 2014 Aug 7;7:504. (IF: 1.980 – Cites: 4)
66. Squillace N, Bresciani E, Torsello A, Bandera A, Sabbatini F, Giovannetti C, Giunta G, Rovati L, Del Bene M, Locatelli V, Gori A. Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients.
J Antimicrob Chemother. 2014 Nov;69(11):3067-75. (IF: 5.313 – Cites: 9)
67. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.
Lancet. 2014 Jul 19;384(9939):241-8. (IF: 45.217)
68. Rozera G, Abbate I, Giombini E, Castagna A, De Luca A, Ceccherini-Silberstein F, Cozzi Lepri A, Cassola G, Torti C, d'Arminio Monforte A, Ippolito G, Capobianchi MR; ICONA Foundation Group. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
J Antimicrob Chemother. 2014 Nov;69(11):3085-94. (IF: 5.313)
69. Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
Retrovirology. 2014 Jun 24;11:49. (IF: 4.185 – Cites 25)
70. Cogliandro V, Lapadula G, Bandera A, Muscatello A, Marcolin R, Abbruzzese C, Rona R, Gori A. ECMO: an alternative support for acute respiratory failure caused by tuberculosis?
Int J Tuberc Lung Dis. 2014 Jul;18(7):879-81. (IF: 2.148 – Cites:1)
71. Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.
HIV Med. 2014 Nov;15(10):595-603. (IF: 3.988)
72. Zanini F, Carugati M, Schiroli C, Lapadula G, Lombardi A, Codecasa L, Gori A, Franzetti F. Mycobacterium tuberculosis Beijing family: analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan.
Infect Genet Evol. 2014 Jul;25:14-9. (IF: 3.015 – Cites: 7)

73. Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. **BMC Nephrol.** 2014 Mar 25;15:51. (IF: 1.690)
74. van Hest NA, Aldridge RW, de Vries G, Sandgren A, Hauer B, Hayward A, Arrazola de Oñate W, Haas W, Codecasa LR, Caylà JA, Story A, Antoine D, **Gori A**, Quabeck L, Jonsson J, Wanlin M, Orcau À, Rodes A, Dedicoat M, Antoun F, van Deutekom H, Keizer S, Abubakar I. Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement. **Eurosurveill.** 2014 Mar 6;19(9). pii: 20728. (IF: 5.722 – Cites: 32)
75. de Vries G, Aldridge RW, Cayla JA, Haas WH, Sandgren A, van Hest NA, Abubakar I; Tuberculosis in European Union Big Cities Working Group. Epidemiology of tuberculosis in big cities of the European Union and European Economic Area countries. **Eurosurveill.** 2014 Mar 6;19(9). pii: 20726. (IF: 5.722)
76. Leone S, Bisi L, Rossi M, **Gori A**. Comment on "Management of infections in cirrhotic patients: report of a consensus conference" S Faggioli et al. [Dig liver dis 2014;46:204-212]. **Dig Liver Dis.** 2014 Jun;46(6):573-4. (IF: 2.963 – Cites:1)
77. Mangioni D, Bandera A, Muscatello A, Squillace N, Crivellaro C, Guerra L, Messa C, **Gori A**. Focal bone lesions in HIV-positive patient treated with tenofovir. **BMC Infect Dis.** 2014 Mar 6;14:131. (IF: 2.613 – Cites: 3)
78. Shive CL, Mudd JC, Funderburg NT, Sieg SF, Kyi B, Bazdar DA, Mangioni D, **Gori A**, Jacobson JM, Brooks AD, Hardacre J, Ammori J, Estes JD, Schacker TW, Rodriguez B, Lederman MM. Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. **J Infect Dis.** 2014 Aug 15;210(4):619-29. (IF: 5.997 – Cites: 27)
79. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. **BMC Infect Dis.** 2014 Feb 12;14:79. (IF: 2.613)
80. Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. **J Antimicrob Chemother.** 2014 Mar;69(3):735-41. (IF: 5.313)
81. Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Alice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chiriani A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, **Gori A**, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. **Infection.** 2014 Feb;42(1):61-71. (IF: 2.618 – Cites: 7)
82. d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤ 50 copies/ml in an observational setting. **Antivir Ther.** 2014;19(3):319-24. (IF: 3.020)
83. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team. Dolutegravir versus

raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Lancet. 2013 Aug 24;382(9893):700-8. (IF: 39.207)

84. Lapadula G, Zanini F, Codecasa L, Franzetti F, Ferrarese M, Carugati M, Mazzola E, Schirotti C, Motta D, Lemmi D, **Gori A.** Influence of Hospitalization upon Diagnosis on the Risk of Tuberculosis Clustering. **Mediterr J Hematol Infect Dis.** 2013 Nov 20;5(1):e2013071. (IF: 1.41)
85. Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. **BMC Infect Dis.** 2013 Oct 9;13:471. (IF: 3.22)
86. De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, **Gori A,** Sighinolfi L, Giacometti A, Capobianchi MR, D'Avino A, Iacoviello L, Cauda R, D'Arminio Monforte A. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. **BMC Infect Dis.** 2013 Sep 3;13:414. (IF: 2.561 – Cites: 27)
87. Leone S, Rossi M, Bisi L, **Gori A,** Esposito S. Antibiotic dose adjustment in patients with advanced liver disease. **Aliment Pharmacol Ther.** 2013 Sep;38(5):561-2. (IF: 4.62 – Cites: 4)
88. Galizzi N, Tortoli E, **Gori A,** Morini F, Lapadula G. A case of mild pulmonary disease due to Mycobacterium shimoides with a favorable outcome. **J Clin Microbiol.** 2013 Oct;51(10):3467-8. (IF: 4.232)
89. Maloberti A, Giannattasio C, Dozio D, Betelli M, Villa P, Nava S, Cesana F, Facchetti R, Giupponi L, Castagna F, Sabbatini F, Bandera A, **Gori A,** Grassi G, Mancina G. Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function. **Metab Syndr Relat Disord.** 2013 Dec;11(6):403-11. (IF: 1.77 – Cites: 14)
90. Leone S, Rossi M, Bisi L, **Gori A,** Esposito S. Antimicrobial therapy duration: a major matter in the management of severe infections. **Int J Antimicrob Agents.** 2013 Sep;42(3):287-8. (IF: 4.259 – Cites:3)
91. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. **AIDS.** 2013 Nov 13;27(17):2735-48. (IF: 6.557)
92. Soria A, **Gori A.** After first-line ART: towards an evidence-based SECOND-LINE. **Lancet.** 2013 Jun 15;381(9883):2062-3. (IF: 39.207 – Cites:2)
93. Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, **Gori A,** Monforte Ad; ICONA Foundation Study. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. **AIDS.** 2013 Mar 13;27(5):769-79. (IF: 6.557 – Cites: 26)
94. Bandera A, Verga L, Perseghin P, Incontri A, Pioltelli PE, **Gori A.** Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies. **AIDS.** 2013 Mar 27;27(6):1037-9. (IF: 6.557 – Cites:1)
95. Antonucci G, Mazzotta F, Angeletti C, Girardi E, Puoti M, De Stefano G, Grossi P, Petrosillo N, Pagano G, Cassola G, Orani A, Sagnelli C, Armignacco O, Sagnelli E; Coorte Epatiti B SIMIT/COESI-B (HIV) Group. Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy. **BMC Res Notes.** 2013 Apr 17;6:153. (IF: 1.98)
96. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albin L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez

- E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Beloso WH, Leyes M, Campins A, Mondí A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negro E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium.; INSIGHT.; Swiss HIV Cohort Study. [Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.](#)
Clin Infect Dis. 2013 Jul;57(1):112-21. (IF: 9.416)
97. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. [Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.](#)
J Infect Dis. 2013 May 1;207(9):1359-69. (IF: 5.778)
98. Efsen AM, Pantelev AM, Grint D, Podlekareva DN, Vassilenko A, Rakhmanova A, Zeltina I, Losso MH, Miller RF, Girardi E, Caylá J, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Lundgren JD, Mocroft A, Kirk O; HIV/TB Study Group. [TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality.](#)
Biomed Res Int. 2013;2013:373601. (IF: 3.53)
99. Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garsen J, Clerici M, Lange JM; for the BITE (Blinded Nutritional Study for Immunity and Tolerance Evaluation) Study Team. [The Immunomodulatory Nutritional Intervention NR100157 Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy \(The BITE Study\).](#)
Clin Infect Dis. 2013 Jul;57(1):139-46. (IF: 9.416 – Cites: 19)
100. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; [Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs \(D:A:D\) study.](#) D:A:D Study Group.
J Int AIDS Soc. 2012 Oct 10;15(2):17426. (IF: 4.2017)
101. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaud R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). [Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.](#)
Int J Epidemiol. 2012 Dec;41(6):1807-20. (IF: 6.414)
102. Girardi E, Scognamiglio P, Angeletti C, Gori A, Buonfrate D, Arlotti M, Mazzarello G, Castagna A, Andreoni M, d'Arminio Monforte A, Antinori A, Ippolito G; [Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.](#) I.Co.Na Foundation Study.
BMC Health Serv Res. 2012 Feb 15;12:38. (IF: 1.773)
103. Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Alice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. [Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.](#)
New Microbiol. 2012 Jan;35(1):17-25. (IF: 1.667 – Cites: 24)
104. Airoldi M, Bandera A, Trabattoni D, Tagliabue B, Arosio B, Soria A, Rainone V, Lapadula G, Annoni G, Clerici M, Gori A. [Neurocognitive impairment in HIV-infected naive patients with advanced disease: the role of virus and intrathecal immune activation.](#)
Clin Dev Immunol. 2012;2012:467154. (IF: 3.064 – Cites: 38)

- 105.** Girardi E, Palmieri F, Angeletti C, Vanacore P, Matteelli A, **Gori A**, Carbonara S, Ippolito G. [Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis.](#) **Clin Dev Immunol.** 2012; 2012:931325. (IF: 3.064 – Cites: 14)
- 106.** Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Florida M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; [Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.](#) Italian HIV Guidelines Working Group. **New Microbiol.** 2012 Apr;35(2):113-59. (IF: 1.667)
- 107.** Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, Di Giacomo C, d'Arminio Monforte A, Antinori A; [Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy.](#) ICONA Foundation Study Group. **Am J Hematol.** 2012 Aug;87(8):749-53. (IF: 4.138)
- 108.** De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; [Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.](#) ICoNA Foundation Study Group. **J Acquir Immune Defic Syndr.** 2012 Jul 1;60(3):e98-101. (IF:4.653)
- 109.** Torti C, Paiardini M, **Gori A.** [Immunity to human immunodeficiency virus \(HIV\) infection.](#) **Clin Dev Immunol.** 2012;2012:629356. (IF: 3.064 - Cites:1))
- 110.** Scientific Coordination Committee, Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. [The Less Drugs Regimens \(LDRs\) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.](#) **New Microbiol.** 2012 Jul;35(3):259-77. (IF: 1.667)
- 111.** Lapadula G, Soria A, Bandera A, Squillace N, Sabbatini F, Franzetti F, Migliori GB, **Gori A.** [Unmasking tuberculosis in the era of antiretroviral treatment.](#) **Eur Respir J.** 2012 May;39(5):1064-75. (IF: 6.355 – Cites: 4)
- 112.** Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, Lazzarin A; [Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.](#) Italian HIV Guidelines Working Group. **New Microbiol.** 2011 Apr;34(2):109-46. (IF: 1.667)
- 113.** Carugati M, Zanini F, Schirotti C, **Gori A**, Franzetti F, Hanekom M, van der Spuy GD, Gey van Pittius NC, McEvoy CR, Ndabambi SL, Victor TC, Hoal EG, van Helden PD, Warren RM. [Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and Beijing/W family of Mycobacterium tuberculosis.](#) **J Clin Microbiol.** 2011 Jul;49(7):2780;2781. (IF: 4.068)
- 114.** Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, Cassola G, Vullo V, Carosi G, Antinori A, Tozzi V, Monforte AD; [Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort.](#) Icona Foundation Study Group. **J Acquir Immune Defic Syndr.** 2011 Oct 1;58(2):163-72. (IF: 4.425)
- 115.** Soria A, Rossi M, Muscatello A, **Gori A.** [HIV testing: a must for patients with inflammatory bowel disease?](#) **Am J Gastroenterol.** 2011 Sep;106(9):1727-8. (IF: 7.282 – Cites: 7)
- 116.** Soria A, Guerini FR, Bandera A, Bolognesi E, Uglietti A, Fusco C, Zucchi P, Maserati R, Rizzardini G, Clerici M, **Gori A.** [KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy.](#) **PLoS One.** 2011;6(11):e27349. (IF: 4.092 – Cites: 14)

117. Soria A, Airoidi M, Migliorino G, Squillace N, Bandera A, Lapadula G, **Gori A**. [Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?](#) **J Antimicrob Chemother.** 2011 May;66(5):1190-1. (IF: 5.068)
118. Guerini FR, Lo Caputo S, **Gori A**, Bandera A, Mazzotta F, Uglietti A, Zanzottera M, Maserati R, Clerici M. [Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals.](#) **J Infect Dis.** 2011 May 1;203(9):1235-9. (IF: 6.410 – Cites: 33)
119. Marchetti G, Cozzi-Lepri A, Merlini E, Bellistri GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'Arminio Monforte A; [Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.](#) ICONA Foundation Study Group. **AIDS.** 2011 Jul 17;25(11):1385-94. (IF: 6.245)
120. **Gori A**, Rizzardini G, Van't Land B, Amor KB, van Schaik J, Torti C, Quirino T, Tincati C, Bandera A, Knol J, Benlhassan-Chahour K, Trabattoni D, Bray D, Vriesema A, Welling G, Garssen J, Clerici M. [Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial.](#) **Mucosal Immunol.** 2011 Sep;4(5):554-63. (IF: 6.963 – Cites: 95)
121. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, Castagna A, Nasta P, Ladisa N, Giacometti A, d'Arminio Monforte A, **Gori A**; [Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure.](#) ICONA Foundation Study Group. **HIV Med.** 2011 Jan;12(1):4-13. (IF: 3.006 – Cites: 36)
122. Prosperi MC, Cozzi-Lepri A, Antinori A, Cassola G, Torti C, Ursitti MA, Pellizzer GP, Giacometti A, d'Arminio Monforte A, De Luca A; [Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008.](#) Icona Foundation Study Group. **HIV Med.** 2011 Mar;12(3):174-82. (IF: 3.006)
123. Bandera A, Rossi M, **Gori A**. [Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4\(+\) T cell depletion.](#) **AIDS Res Hum Retroviruses.** 2011 May;27(5):459-60.. (IF: 2.157)
124. Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; [High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.](#) D:A:D study group. **AIDS.** 2010 Jan 28;24(3):427-35. (IF: 6.348)
125. Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A, Antonelli G, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bonn I, Bruzzone B, Callegaro AP, Cammarota R, Canducci F, Ceccherini-Silberstein F, Clementi M, Monforte AD, De Luca A, Di Biagio A, Di Gianbenedetto S, Di Perri G, Di Pietro M, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, **Gori A**, Leoncini F, Maggiolo F, Maserati R, Mazzotta F, Micheli V, Meini G, Monno L, Mussini C, Nozza S, Paolucci S, Parisi S, Pecorari M, Pizzi D, Quirino T, Re MC, Rizzardini G, Santangelo R, Soria A, Stazi F, Sterrantino G, Turriziani O, Viscoli C, Vullo V, Lazzarin A, Perno CF; [Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.](#) OSCAR Study Group. **New Microbiol.** 2010 Jul;33(3):195-206. (IF: 1.667 – Cites: 39)
126. Sabbatini F, Bandera A, Ferrario G, Trabattoni D, Marchetti G, Franzetti F, Clerici M, **Gori A**. [Qualitative immune modulation by interleukin-2 \(IL-2\) adjuvant therapy in immunological non responder HIV-infected patients.](#) **PLoS One.** 2010 Nov 29;5(11):e14119. (IF: 4.411 – Cites: 16)
127. Airoidi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, **Gori A**, Suter F, Maggiolo F. [One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.](#) **Patient Prefer Adherence.** 2010 May 13;4:115-25. (IF: 1.143 – Cites: 140)

128. Bandera A, Ferrario G, Saresella M, Marventano I, Soria A, Zanini F, Sabbatini F, Airoidi M, Marchetti G, Franzetti F, Trabattoni D, Clerici M, Gori A. [CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals.](#) **PLoS One.** 2010 May 24;5(5):e10788. (IF: 4.411 – Cites: 50)
129. Marchetti G, Gazzola L, Trabattoni D, Bai F, Ancona G, Ferraris L, Meroni L, Galli M, Clerici M, Gori A, D'Arminio Monforte A. [Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART.](#) **AIDS.** 2010 Jun 19;24(10):1455-60. (IF: 6.348 – Cites: 16)
130. Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, Bandera A, Capetti A, Rizzardini G, Clerici M. [Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.](#) **AIDS.** 2010 Aug 24;24(13):1991-2000. (IF: 6.348 – Cites: 98)
131. Giannattasio C, Failla M, Squillace N, Dolara A, Cesana F, Sabbatini F, Bandera A, Facchetti R, Dozio D, Gori A, Mancina G. [Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study.](#) **Blood Press.** 2010 Dec;19(6):344-50. (IF: 1.256 – Cites: 3)
132. Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R; [Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.](#) MASTER Cohort. **Curr HIV Res.** 2010 Apr;8(3):186-93. (IF: 1.923)
133. Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, Torti C, Costantini A, Narciso P, Ghinelli F, Antinori A, d'Arminio Monforte A; [Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.](#) IcoNA Foundation Study Group. **Clin Infect Dis.** 2010 May 1;50(9):1316-21. (IF: 8.186)
134. Devaux I, Manissero D, Fernandez de la Hoz K, Kremer K, van Soolingen D; [Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007.](#) EuroTB network. **Eurosurveill.** 2010 Mar 18;15(11). (IF: 6.153)
135. Citerio G, Sala F, Patruno A, Gori A, Grioni D, Rossi M, Giussani C, Grimaldi M. [Influenza A \(H1N1\) encephalitis with severe intracranial hypertension.](#) **Minerva Anestesiol.** 2010 Jun;76(6):459-62. (IF: 2.581 – Cites: 9)
136. Franzetti F, Codecasa L, Matteelli A, Degli Esposti A, Bandera A, Lacchini C, Lombardi A, Pinsi G, Zanini F, El-Hamad I, Gori A. [Genotyping analyses of tuberculosis transmission among immigrant residents in Italy.](#) **Clin Microbiol Infect.** 2010 Aug;16(8):1149-54. (IF: 4.784 – Cites: 26)
137. Cicconi P, Cozzi-Lepri A, Castagna A, Trearichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; [Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.](#) ICoNA Foundation Study Group. **HIV Med.** 2010 Feb;11(2):104-13. (IF: 3.575)
138. Franzetti F, Codecasa L, Matterelli A, Degli Esposti A, Bandiera A, Lacchini C, Lombardi A, Pinsi G, Zanini F, El-Hamad I, and Gori A. Genotyping Analyses of Tuberculosis Transmission among Immigrant Residents in Northern Italy. **Clin Microbiol Infect** 2010. Aug;16(8):1149-54. (IF: 3.554 – Cites: 26)
139. Lapadula G, Viganò F, Fortuna P, Dolara A, Bramati S, Soria A, Foresti S, Gori A. [Imported ciprofloxacin-resistant *Neisseria meningitidis*.](#) **Emerg Infect Dis.** 2009 Nov;15(11):1852-4. (IF: 6.794 – Cites: 9)
140. Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, Gori A, Gaito S, Clerici M, Chiti A. [FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables.](#) **Eur J Nucl Med Mol Imaging.** 2009 Apr;36(4):640-7. (IF: 4.531)

- 141.** Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. [Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.](#) **AIDS** 2009 27;23(18):2485-95. (IF: 5.842)
- 142.** Lapadula G, Vigano F, Fortuna P, Dolora A, Bramati S, Soria A, Foresti S, and **Gori A.** Ciprofloxacin-Resistant Neisseria Meningitidis: An Importable Disease? **Emerg Infect Dis** 2009 Nov;15(11):1852-4. (IF: 6.449)
- 143.** Soria A, Foresti S, Fortuna P, Dolara A, Bandera A, Lapadula G, Gori A. Unmasked TB or lymphoma in late AIDS-presenters: a difficult differential diagnosis. **Eur Respir J** 2009 Oct;34(4):997-8. (IF: 5.527 – Cites: 2)
- 144.** Lapadula G, Soria A, and **Gori A.** Pharmacotherapy of HIV: focus on Etravirine. **Clinical Medicine: Therapeutics** 2009;1 483-494. (Cites: 3)
- 145.** Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort. [Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.](#) **Infection.** 2009 Oct;37(5):438-44. (IF: 2.051)
- 146.** d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. [Risk of developing specific AIDS-defining illnesses in patients coinfecting with HIV and hepatitis C virus with or without liver cirrhosis.](#) **Clin Infect Dis.** 2009 Aug 15;49(4):612-22 (IF:8.266)
- 147.** Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. [Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.](#) **J Acquir Immune Defic Syndr.** 2009 Aug 15;51(5):574-81. (IF: 4.570)
- 148.** Antinori A, Ammassari A, Torti C, Marconi P, Andreoni M, Angarano G, Bonora S, Castagna A, Cauda R, Clerici M, d'Arminio Monforte A, De Luca A, Di Perri G, Galli M, Girardi E, **Gori A,** Lazzarin A, Lo Caputo S, Mazzotta F, Montella F, Mussini C, Perno CF, Puoti M, Rizzardini G, Rusconi S, Vullo V, Carosi G. [Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy.](#) **Infection** 2009. Jun;37(3):270-82. (IF: 2.049 – Cites: 7)
- 149.** Tincati C, Biasin M, Violin M, Gazzola L, Marchetti G, Piacentini L, Vago L, d'Arminio Monforte A, Balotta C, Franzetti F, Clerici M, and **Gori A.** Early Initiation of HAART Fails, in the Short-Term, to Reverse Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Induced by Acute HIV Infection. **Antivir Ther** 2009;14(3):321-30. (IF: 4.105 – Cites: 40)
- 150.** Marchetti G, Riva A, Cesari M, Bellistri GM, Giannelli E, Casabianca A, Orlandi C, Magnani M, Meroni L, d'Arminio Monforte A, Mussini C, Cossarizza A, Galli M, and **Gori A,** for the Elvis Study Group. HIV-Infected Long-Term Non-Progressors Display a Unique Correlative Pattern between IL-7/IL-7R Circuit and T-Cell Homeostasis. **HIV Med** 2009. Aug;10(7):422-31. (IF: 2.878- Cites: 11)
- 151.** Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, **Gori A,** Gaito S, Clerici M, Chiti A. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. **Eur J Nucl Med Mol Imaging** 2009;36(4):640-7. (IF: 4.625 – Cites: 28)
- 152.** **Gori A,** Franzetti F, Girardi E. Knowledge for XDR Tuberculosis Control Today. **PLoS Medicine** 2009. (IF: 13.50)
- 153.** Bandera A, Trabattoni D, Ferrario G, Cesari M, Franzetti F, Clerici M, **Gori A.** [Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis.](#) **Infection.** 2008 Aug;36(4):368-73. (IF: 1.831 – Cites: 24)

154. Bandera A, Trabattoni D, Pacei M, Fasano F, Suardi E, Cesari M, Marchetti G, Pogliani EM, Franzetti F, Clerici M, Gori A. Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. **PLoS ONE** 2008;3(10):e3616. Epub 2008 Oct 31. (IF: 4.411 – Cites: 3)
155. Bandera A, Trabattoni D, Marchetti G, Molteni C, Ferrario G, Gazzola L, Cesari M, Franzetti F, Clerici M, and **Gori A.** Role of Interferon-g and Granulocyte-Macrophage Colony Stimulating Factor for Pulmonary Aspergillosis. **Infection** 2008 Aug;36(4):368-73. Epub 2008 Jul 19. (IF: 2.049 – Cites: 15)
156. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. **AIDS** 2008;22(16):2143-53. (IF: 5.460)
157. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggin V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M; Icona Foundation Study Group. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. **AIDS** 2008;22(14):1769-78. (IF: 5.460)
158. Marchetti G, Bellistri GM, Tincati C, Borghi E, La Francesca M, Morace G, **Gori A,** d'Arminio Monforte A. Microbial translocation is a determinant of sustained CD4 reconstitution failure in HIV-infected patients on long-term HAART. **AIDS** 2008;22(15):2035-8. (IF: 5.460 – Cites: 234)
159. Ferraris L, Bellistri GM, Pegorer V, Tincati C, Meroni L, Galli M, d'Arminio Monforte A, **Gori A,** and Marchetti G. Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy. **Clin Infect Dis** 2008;46:149-50. (IF: 6.750 – Cites: 6)
160. **Gori A,** Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, Ben Amor K, van Schaik J, Vriesema A, Knol J, Moroni M, and Clerici M. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. **J Clin Microbiol** 2008;46:757-8. (IF: 3.708 – Cites: 152)
161. Gazzola L, Ferrario G, Zanini F, Salerno F, Lombardi A, Zerbi P, Meroni L, Vago L, Moroni M, Franzetti F, and **Gori A.** The usefulness of PCR assay in diagnosing disseminated mycobacterial infection in AIDS patients. **Eur J Clin Microbiol Infect Dis** 2008;27:163-6. (IF: 2.309 – Cites: 1)
162. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Codecasa LR, Spanevello A, Cirillo DM, Gori A; SMIRA/TBNET Study Group. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? **Eur Respir J** 2008;31:904-5. (IF: 5.349)
163. Marchetti G, Tincati C, **Gori A.** The challenge of IL-2 immunotherapy in HIV disease: "no through road" or turning point? **Curr HIV Res** 2008;6:189-99. (IF: 2.653 – Cites: 11)
164. Guerini FR, Delbue S, Zanzottera M, Agliardi C, Saresella M, Mancuso R, Maserati R, Marchioni E, **Gori A,** Ferrante P. Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. **Biomed Pharmacother** 2008;62:26-30. (IF: 1.418 – Cites: 24)
165. Migliori GB, Lange C, Centis R, Sotgiu G, Mütterlein R, Hoffmann H, Kliiman K, De Iaco G, Lauria FN, Richardson MD, Spanevello A, Cirillo DM, Gori A, TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. **Eur Respir J** 2008;31:1155-9. (IF: 5.349)

- 166.** Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungousova OS, Ferrara G, Cirillo DM, **Gori A**, Matteelli A, Spanevello A, Codecasa LR, Raviglione MC; [Clinical and operational value of the extensively drug-resistant tuberculosis definition](#). SMIRA/TBNET Study Group.
Eur Respir J 2007 Oct;30(4):623-6. (IF: 5.545 – Cites: 208)
- 167.** Migliori GB, Besozzi G, Girardi E, Lange C, Kliiman K, Toungousova OS, Ferrara G, Cirillo D, **Gori A**, Matteelli A, Spavanello A, Codecasa LR, Raviglione M and SMIRA/TBNET Study Group. Clinical and operational value of the XDR-TB definition.
Eur Respir J 2007;30:623-6. (IF: 5.349)
- 168.** Bongiovanni M, **Gori A**, Cozzi Lepri A, Antinori A, de Luca A, Pagano G, Chiodera A, Puoti M, d'Arminio Monforte A. Is CD4 percentage a better marker of immune-suppression than CD4 absolute count in HIV-infected patients with cirrhosis?
Clin Infect Dis 2007;1;45:650-3. (IF: 6.750 – Cites: 10)
- 169.** Tincati C, Marchetti G, and **Gori A**. Treating HIV: Current Advances in Immune-Based Therapy for HIV Infection.
Eur Infect Dis 2007;1:38-39. (IF: 5.349)
- 170.** Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De Iaco G, **Gori A**, Raviglione MC and SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis, Italy and Germany.
Emerg Infect Dis 2007;13:780-2. (IF: 5.775 – Cites: 136)
- 171.** Gazzola L, Saresella M, Marventano I, Tincati C, Zanini F, **Gori A**. FoxP3 mRNA Expression in Regulatory T Cells from Tuberculosis Patients.
Am J Resp Crit Care Med 2006;174(3):356-357. (IF: 9.091 – Cites: 10)
- 172.** Orunesu E, **Gori A**, Clerici M, Pacei M, Marzo K, Bechi G, Cesari M, Castelletti E, Lucignani G, Chiti A. Usefulness of FDG-PET imaging in HIV infected individuals for visualization and quantification of lymphatic tissue activation.
Eur J Nucl Med Mol Imaging 2006;33:192-194. (IF: 4.041)
- 173.** Marchetti G, **Gori A**, Molteni C, Taskaris G, Casabianca A, Magnani M, Franzetti F, Clerici M, Moroni M, Bertoli A, Gori C, Perno CF, d'Arminio Monforte A, Galli M, Meroni L. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological response to HAART.
AIDS 2006;20(13):1727-1736. (IF: 5.835 – Cites: 113)
- 174.** Bandera A, Gazzola L, Franzetti F, Clerici M, and **Gori A**. Unusual T-cell Repopulation after Autologous Stem Cell Transplantation for HIV-associated Lymphoma.
Transplantation 2006;27;81(12):1752-3. (IF: 3.972)
- 175.** Franzetti F, Zanini F, Gazzola L, Codecasa L, and **Gori A**. Molecular epidemiology of tuberculosis.
Clin Infect Dis 2006;42:1498-9. (IF: 6.510 – Cites: 1)
- 176.** Brudey K, Driscoll JR, Rigouts L, Prodinger W, **Gori A**, Al-Hajj SAM, et al. An Appraisal of the Geographic Prevalence of Major Genotypic Families of *Mycobacterium tuberculosis* Complex Through the Updated SpolDB4 database.
BMC Microbiol 2006;6 (1):6-23. (IF: 2.896 – Cites: 946)
- 177.** Franzetti F, Grassini A, Piazza M, Degl'Innocenti M, Bandiera A, Gazzola L, Marchetti G, and **Gori A**. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rationale empiric antibiotic therapy.
Infection 2006;34(1):9-16. (IF: 2.368 – Cites: 51)
- 178.** Trabattoni D, Schenal M, Cesari M, Venuto A, Dissoni F, Goldberg B, **Gori A** and Clerici M. Low Interleukin-10 production is associated with development of diabetes in HIV-infected, HAART-treated patients.
Med Microbiol Immunol 2006;26:1-8. (IF: 4.185 – Cites: 10)
- 179.** Bandera A, Marchetti G, and **Gori A**. Immunomodulants in HIV infection.
Expert Opin Ther Pat 2005;15(9):1115-1131. (IF: 4.480)

- 180.** Bulgheroni E, Bandera A, Galli M, **Gori A**, Rusconi S. Analysis of the Env V3 sequences obtained from patients with HIV-1 infection treated with the immune modulant agent tucaresol.
AIDS Res Hum Retroviruses 2005;21(9):815-819. (IF: 2.375)
- 181.** **Gori A**, Bandera A, Marchetti G, Degli Esposti A, Catozzi L, Nardi GP, van Embden JDA, van Soolingen D, Moroni M, and Franzetti F. Spoligotyping and *Mycobacterium tuberculosis*.
Emerg Infect Dis 2005;11(8):1242-1248. (IF: 5.643 – Cites: 82)
- 182.** **Gori A**, Degli Esposti A, Bandera A, Sola C, Marchetti G, Ferrario G, Salerno F, Goyal M, Diaz R, Gazzola L, Codecasa L, Penati V, Rastogi N, Moroni M, and Franzetti F. Comparison between Spoligotyping and IS6110 Restriction Fragment Length Polymorphisms in Molecular Genotyping Analysis of *Mycobacterium tuberculosis* Strains.
Mol Cell Probes 2005;19:236-244. (IF: 2.019 – Cites: 24)
- 183.** Marchetti G, Franzetti F, and **Gori A**. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant Interleukin-2 fill the gap?
J Antimicrob Chemother 2005;55(4):401-9. (IF: 3.886 – Cites: 44)
- 184.** Molteni C, Gazzola L, Cesari M, Lombardi A, Salerno F, Tortoli E, Codecasa L, Penati V, Franzetti F, and **Gori A**. *Mycobacterium lentiflavum* infection in immunocompetent patient.
Emerg Infect Dis 2005;11(1):119-122. (IF: 5.643 – Cites: 29)
- 185.** **Gori A**, Trabattoni D, Bandera A, Saresella M, Marchetti G, Rhodes J, McDade H, Panebianco R, Moroni M, Ferrante P, Thomas N, Franzetti F, Bray D, and Clerici M. Immunomodulation Induced by Tucaresol in HIV-Infection: Results of a 16 Weeks Pilot Phase I/II Trial.
Antiviral Therapy 2004;9:603-614. (IF: 6.036 – Cites: 9)
- 186.** Marchetti G, Meroni L, Molteni C, Taskaris G, Gazzola L, Galli M, Clerici M, Moroni M, Franzetti F, and **Gori A**. IL-7/IL-7 Receptor System Regulation Following IL-2 Immunotherapy in HIV-Infected Patients.
Antiviral Therapy 2004;9:447-452. (IF: 6.036 – Cites: 18)
- 187.** Migliori GB, Centis R, Fattorini Lanfranco, Besozzi G, Saltini C, Scarpaio C, Cirillo D, **Gori A**, Cassone A, Piersimoni C. *Mycobacterium tuberculosis* Complex Drug resistance in Italy.
Emerg Infect Dis 2004;10:752-753. (IF: 5.643 – Cites: 8)
- 188.** Gazzola L, Cesari M, Salerno F, Franzetti F, and **Gori A**. Clinical and therapeutic management of pulmonary *Mycobacterium xenopi* infection in HIV-positive patients.
Clin Infect Dis 2004;38:1642-1644. (IF: 6.510 – Cites: 6)
- 189.** Marchetti G, Meroni L, Molteni C, Bandiera A, Franzetti F, Galli M, Moroni M, Clerici M, and **Gori A**. Interleukin-2 Immunotherapy Exerts a Differential Effect on CD4+ and CD8+ T-Cell Dynamics.
AIDS. 2004;18:221-226. (IF: 5.893 – Cites: 28)
- 190.** Scarpellini P, Carrera P, Cichero P, Gelfi C, **Gori A**, Ferrari M, Zingale A, Lazzarin A. Detection of resistance to isoniazid by denaturing gradient-gel electrophoresis DNA sequencing in *Mycobacterium tuberculosis* clinical isolates.
New Microbiol. 2003;26(4):345-51. (IF: 1.00 – Cites: 6)
- 191.** Matteelli A, Pinsi G, **Gori A**, Mastaglia F, El-Hamad I, Bombana E, Degli Esposti A, Bandera A, Tedoldi S, Casalini C, Scolari C, Carosi GP. Geographic clustering of tuberculosis among immigrants in Italy.
Int J Tuberc Lung Dis. 2003;7(10):967-72. (IF: 1.888 Cites: 9)
- 192.** Migliori GB, Centis R, Fattorini L, Vaccarino P, Besozzi G, Saltini C, Orefici G, Iona E, Piersimoni C, Scarparo C, Cirillo D, **Gori A**, Cassone A, and the SMIRA (Italian Multicentre Study on Resistance to Antituberculosis drugs) Study Group. Monitoring the quality of laboratories. Proficiency testing for drug susceptibility testing and prevalence of drug resistance in Italy: reports of the SMIRA study results, year 2000.
Eur Resp J. 2003;21:129-134. (IF: 3.947 – Cites 14)
- 193.** Marchetti G, Meroni L, Franzetti F, and **Gori A**. Clinical Value of Adjunctive Interleukin-2: Clarifications and Corrections.
J Infect Dis. 2003;187:340-341. (IF: 4.481)

- 194.** Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, Molteni C, Trabattoni D, Fossati S, Clerici M, Galli M, Moroni M, Franzetti F, and **Gori A**. Low-Dose Prolonged Intermittent Interleukin-2 Adjuvant Therapy: Results of a Randomized Trial on HIV+ Patients with Advanced Immune Impairment. **J Infect Dis.** 2002 Sep 1;186(5):606-16. (IF: 4.857 – Cites: 64)
- 195.** Moro ML, Salamina G, **Gori A**, Penati V, Sacchetti R, Mezzetti F, Infuso A, Sodano L. Two-year population-based molecular epidemiological study of tuberculosis transmission in the metropolitan area of Milan, Italy. **Eur J Clin Microbiol Infect Dis.** 2002;21:114-122. (IF: 2.061 – Cites: 41)
- 196.** Bandera A, **Gori A**, Catozzi L, Degli Esposti A, Marchetti G, Molteni C, Ferrario G, Codecasa L, Penati V, Matteelli A, and Franzetti F. Exogenous reinfection in tuberculosis: potential role of epidemiological features in a low-incidence tuberculosis area. **J Clin Microbiol.** 2001;39:2213-2218. (IF: 3.537 – Cites: 183)
- 197.** Zerbi P, Schonau A, Bonetto S, **Gori A**, Costanzi G, Duca P, and Vago L. Amplified in situ hybridization with peptide nucleic acid probes for differentiation of Mycobacterium tuberculosis complex and nontuberculous Mycobacterium species on formalin-fixed, paraffin-embedded archival biopsy and autopsy samples. **Am J Clin Pathol.** 2001;116(5):770-5. (IF: 3.136 – Cites: 23)
- 198.** Ferrario G, **Gori A**, Rossi A, Catozzi L, Molteni C, Marchetti G, Bandera A, Rossi MC, Degli Esposti A, and Franzetti F. PCR-Hybridization Assay for Mycobacterium avium complex: Optimization of Detection in Human Peripheral Blood. **J Clin Microbiol.** 2001;39:1638-1643. (IF: 3.537 – Cites: 4)
- 199.** Dubreuil-Lemaire ML, **Gori A**, Panellatti G, Vittecoq D, Taroux F, Palisses R, Gharakhanian S, Rozembaum W, & the GCS 309 European Study Group. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. **Eur J Haematol.** 2000;65(5):337-43. (IF: 2.004 – Cites: 22)
- 200.** **Gori A**, Rossi MC, Marchetti G, Trabattoni D, Molteni C, Cogliati M, Bandera A, Clerici M, and Franzetti F. Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. **AIDS.** 2000;14:1859-1861. (IF: 6.881 – Cites: 16)
- 201.** Bandera A, **Gori A**, Rossi MC, Degli Esposti A, Ferrario G, Marchetti G, Tocalli L, and Franzetti F. A case of costochondral abscess due to Corynebacterium minutissimum in an HIV-infected patient. **J Infect.** 2000;41:103-105. (IF: 1.188 - Cites: 16)
- 202.** **Gori A**, Rossi MC, Trabattoni D, Marchetti G, Fusi ML, Molteni C, Bandera A, Clerici M, and Franzetti F. TNF- α increase production during thalidomide treatment in patients with tuberculosis and HIV coinfection. **J Infect Dis.** 2000;182:639. (IF: 4.910 – Cites: 18)
- 203.** Rossi MC, **Gori A**, Zehender G, Marchetti G, Ferrario G, De Maddalena C, Catozzi L, Bandera A, Degli Esposti A, and Franzetti F. A PCR-Colorimetric Microwell Plate Hybridization Assay for Detection of M. tuberculosis and M. avium from Culture Samples and Ziehl-Neelsen Positive Smears. **J Clin Microbiol.** 2000;38: 1772-1776. (IF: 3.537 – Cites 19)
- 204.** Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, **Gori A**, Gervasoni C, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Galli M, Rusconi S, and Moroni M. Genotypic prevalence of transmitted nucleoside analogs-resistant HIV-1 strains, pre-existing mutations in protease coding region and outcome after treatment in recently infected individuals. **J Biol Regul Homeost Agents.** 2000;14(1):51-7. (IF: 5.18 – Cites: 5)
- 205.** Tambussi G, **Gori A**, Capiluppi B, Balotta C, Papagno L, Morandini B, Di Pietro M, Ciuffreda D, Saracco A, and Lazzarin A. Neurological Symptoms during Primary Human Immunodeficiency Virus (HIV) Infection Correlate with High Levels of HIV-RNA in Cerebrospinal Fluid. **Clin Infect Dis.** 2000;30:962-965. (IF: 6.510 – Cites: 67)
- 206.** Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, **Gori A**, Gervasoni C, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Galli M, Rusconi S, and Moroni M. Genotypic prevalence of transmitted nucleoside analogs-resistant HIV-1 strains, pre-existing mutations in protease coding region and outcome after treatment in recently infected individuals.

- Antiviral Therapy. 2000;5:7-14. (IF: 9.240 – Cites 61)**
- 207.** Moro ML, Errante I, Infuso A, Sodano L, **Gori A**, Orcese CA, Salamina G, D'Amico C, Besozzi G, Caggese L. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug resistant tuberculosis among HIV patients in Italy.
Int J Tuberc Lung Dis. 2000;4:61-68. (IF: 1.888 – Cites 61)
- 208.** Serraino A, Marchetti G, Sanguinetti V, Rossi MC, Zanoni RG, Catozzi L, Bandera A, Dini V, Mignone VG, Franzetti F, and **Gori A**. Monitoring of transmission of tuberculosis between wild boars and cattle: genotypical analysis by molecular epidemiology techniques.
J Clin Microbiol. 1999;37:2766-2771. (IF: 3.537 – Cites: 107)
- 209.** Scarpellini P, Braglia S, Carrera P, Cedri M, Cichero P, Colombo A, Crucianelli R, **Gori A**, Ferrari M, and Lazzarin A. Detection of rifampin resistance in Mycobacterium tuberculosis by double gradient-denaturing gradient gel electrophoresis.
Antimicrob Agent Chemother. 1999;43:2550-2554. (IF: 4.379 – Cites: 43)
- 210.** Franzetti F, **Gori A**, Iemoli E, Meraviglia P, Mainini F, Quirino T, Degli Esposti A, Degli Innocenti M, Grassini A, Nardi GF, and Cargnel A. Outcome of multidrug resistant tuberculosis in HIV-infected patients.
Clin Infect Dis. 1999;29:553-60. (IF: 6.510 – Cites: 26)
- 211.** Codecasa LR, Porretta AD, **Gori A**, Franzetti F, Degli Esposti A, Lizioli A, Carreri V, Di Proietto MC, Perrozzello F, Besozzi G. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996.
Int J Tuberc Lung Dis. 1999;3(7):589-595. (IF: 1.888 - Cites: 53)
- 212.** **Gori A**, Catozzi L, Rossi MC, Marchetti G, Degli Esposti A, Bandera A, Ferrario G, e Franzetti F. Studio di correlazione tra genotipo ed aspetti clinico-epidemiologici della tubercolosi in pazienti HIV-positivi.
Microbiologia Medica. 1999;14 (1):31-34.
- 213.** van Soolingen D, Bauer J, Ritacco V, Cordoso Leao S, Pavlik I, Vincent V, Rastogi N, **Gori A**, Bodmer T, Garzelli C and Garcia MJ. IS1245 restriction fragment length polymorphism typing of Mycobacterium avium isolates: a proposal for standardization.
J Clin Microbiol. 1998;36:3051-3054. (IF: 3.537 – Cites: 150)
- 214.** Marchetti G, **Gori A**, Catozzi L, Vago L, Nebuloni M, Rossi MC, Degli Esposti A, Bandera A, and Franzetti F. Evaluation of polymerase chain reaction in the detection of Mycobacterium tuberculosis from formalin-fixed, paraffin-embedded tissue: comparison among four amplification assays.
J Clin Microbiol. 1998;36:1512-1517. (IF: 3.537 – Cites: 135)
- 215.** **Gori A**, Rusconi S, Negri C, Marchetti G, Ferrario G, Sampietro R, and Franzetti F. Videothoroscopic resection of pulmonary bullous lesion and pleurectomy in AIDS patients.
AIDS Reader. 1998;8(3):104-106. (IF: 0.22)
- 216.** Angarano G, Carbonara S, **Gori A** and the Italian Drug-Resistant Tuberculosis Study Group. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy.
Int J Tuberc Lung Dis. 1998;2(4):303-311. (IF: 1.888 – Cites: 17)
- 217.** Vago L, Barberis M, **Gori A**, Scarpellini P, Sala E, Nebuloni M, Bonetto S, Cannone M, Marchetti G, Franzetti F, Costanzi G. Nested polymerase chain reaction (PCR) to M. tuberculosis IS6110 sequence on formalin-fixed, paraffin-embedden tissues with granulomatous diseases for rapid diagnosis of tuberculosis.
Am J Clin Pathol. 1998;109:411-415. (IF: 3.136 – Cites: 47)
- 218.** Moro ML, **Gori A**, Errante I, Infuso A, Franzetti F, Sodano L, Iemoli E & the Italian MDR-TB Outbreak Study Group. An outbreak of multidrug resistant tuberculosis involving HIV-infected patients of two hospitals in Milan Italy.
AIDS. 1998;12: 1095-1102. (IF: 6.881 – Cites: 138)
- 219.** **Gori A**, Marchetti G, Catozzi L, Nigro C, Ferrario G, Rossi MC, Degli Esposti A, Orani A, and Franzetti F. Molecular epidemiology characterization of a multidrug-resistant Mycobacterium bovis outbreak among HIV-positive patients.
AIDS. 1998;12:445-446. (IF: 6.881 – Cites: 9)

- 220.** d'Arminio Monforte A, Testa L, Gianotto M, **Gori A**, Franzetti F, Sollima S, Bini T, and Moroni M. Indinavir related alopecia.
AIDS. 1998;12:328. (IF: 6.881 – Cites: 34)
- 221.** **Gori A**, Franzetti F, Marchetti G, Rossi C, Fusi ML, Ruzzante S, and Clerici M. Clinical and immunological improvement after thalidomide treatment in refractory Mycobacterium avium infection.
Clin Infect Dis. 1998;26:184-185. (IF: 6.510 – Cites: 15)
- 222.** Scarpellini P, Braglia S, Brambilla AM, Dalessandro M, Cichero P, **Gori A**, and Lazzarin A. Detection of rifampin resistance by single-strand conformation polymorphism analysis of cerebrospinal fluid of patients with tuberculosis of the central nervous system.
J Clin Microbiol. 1997;35:2802-2806. (IF: 3.537 – Cites: 38)
- 223.** **Gori A**, Franzetti F, Marchetti G, Catozzi L, Rossi MC, Nardi GP, Degl'Innocenti M, Grassini A, Gismondo MR, Moroni M. Valutazione dell'utilizzo clinico della polymerase chain reaction nella diagnosi di malattia tubercolare.
Giorn It Mal Inf. 1997;3:150-155.
- 224.** Tambussi G, Lillo F, Capiluppi B, Clerici E, **Gori A**, Di Pietro M, Gavazzeni G, Morandini B, Lazzarin A. Primary HIV infection: clinical aspects and monitoring.
J Biol Regul Homeost Agents. 1997;11:53-55. (IF: 5.18)
- 225.** Rusconi S, **Gori A**, Vago L, Marchetti G, Franzetti F. Cutaneous infection caused by Mycobacterium gordonae in an HIV infected patient during antimycobacterial treatment.
Clin Infect Dis. 1997;25:1490-91. (IF: 6.510 – Cites: 23)
- 226.** Franzetti F, **Gori A**, Vezzoli S, Rossi C, Degli Esposti A, Bandera A, Nardi GP, and Rusconi S. Epidemiology of Mycobacterium avium infection in Northern Italy.
AIDS. 1997;11:1065-1066. (IF: 6.881)
- 227.** **Gori A**, Franzetti F, Bestetti G, Catozzi L, Nardi GP, Marchetti G, Rusconi S, Corbellino M. Use of Multiplex PCR assay and DNA Fingerprinting analysis for typing of Multidrug-resistant Mycobacterium tuberculosis strains.
J Inf. 1997;35:322-323. (IF: 1.882)
- 228.** Salamina G, Infuso A, Sodano L, **Gori A**, Penati V, Serembe G, Girardi E, Tuzza B, Catozzi L, Moro ML. Studio di popolazione sulla trasmissione della tubercolosi (TB) in pazienti AIDS e nella popolazione generale nell'area metropolitana di Milano: risultati preliminari del primo anno di studio, 1995-1996.
Giorn It Mal Inf. 1997;3(S1):127-130.
- 229.** Franzetti F, **Gori A**, Iemoli E, Meraviglia P, Quirino T, Grassini A, Degl'Innocenti M, Degli Esposti A, Mainini F, Nardi G, Rossi R, Gismondo MR, Cargnel A. Un'epidemia di tubercolosi multiresistente in pazienti con AIDS in un Ospedale Milanese.
Giorn It Mal Inf. 1997;3(S1):25-28.
- 230.** **Gori A**, Franzetti F, Marchetti G, Catozzi L, Rossi MC, Nardi G, Degl'Innocenti M, Grassini A, Gismondo MR, Moroni M. Valutazione dell'utilizzo clinico dell'amplificazione del frammento mtp-40 mediante PCR nella diagnosi tubercolare.
Giorn It Mal Inf. 1997;3(S1):189-190.
- 231.** d'Arminio Monforte A, Cinque P, Vago L, Rocca A, Castagna A, Gervasoni C, Terreni MR, Novati R, **Gori A**, Lazzarin A, Moroni M. A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients.
J Neurol. 1996;244:35-39. (IF: 3.345 – Cites: 60)
- 232.** Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, **Gori A**, Violin M, Zanchetta N, Moroni M, Balotta C, and Galli M. Viral load, viral phenotype modification, drug susceptibility, and reverse transcriptase mutations during the first six months of zidovudine monotherapy in HIV-1 infected subjects.
Antiviral Therapy. 1996;1(4):211-219. (IF: 9.240 – Cites: 7)
- 233.** Hermans P, Rozembaum W, Jou A, Castelli F, Borleffs J, Gray S, Ward N, **Gori A**, Ciaffi L, Ferrè C, Zamora L, Lang J, Ammassari A, Clumeck N. Filgastrim (r-metG-CSF) to treat neutropenia and support myelosuppressive medication dosing in HIV infection.

- AIDS. 1996;10:1627-1633. (IF: 6.881 – Cites: 44)**
- 234. Gori A, Franzetti F, Marchetti G, Catozzi L, Corbellino M.** Specific detection of *Mycobacterium tuberculosis* by mtp40 nested PCR.
J Clin Microbiol. 1996;34:2866-2867. (IF: 3.537 – Cites: 15)
- 235. Negri C, Rusconi S, Gori A, Riva C, Balotta C, and Galli M.** AIDS in a long-term HIV-1-infected patient with a stable high CD4+ cell count and conserved CD4+CD45RO+ subpopulation.
AIDS. 1996;10:1737-1738. (IF: 6.881 – Cites: 2)
- 236. Rusconi S, Milazzo L, Gori A, Moscatelli GC, Testa L, Manzulli T, and Negri C.** Serious heart involvement with central nervous system impairment in bilateral pneumonia due to *Mycoplasma pneumoniae*.
Clin Microbiol Newsletter. 1996;18:182-183. (IF: 0.44)
- 237. Gori A, Espinasse F, Deplano A, Nonhoff C, Nicolas MH, and Struelens MJ.** Comparison of pulsed-field gel electrophoresis and randomly amplified DNA polymorphism analysis for typing extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae*.
J Clin Microbiol. 1996;34:2448-2453. (IF: 3.537 – Cites 101)
- 238. d'Arminio Monforte A, Vago L, Gori A, Antinori S, Franzetti F, Antonacci CM, Sala E, Catozzi L, Testa L, Esposito R, Nebuloni M, Moroni M.** Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS.
Eur J Clin Microbiol Infect Dis. 1996;15:453-458. (IF: 6.510 – Cites: 37)
- 239. Ridolfo AL, Santambrogio S, Mainini F, Vago L, Gervasoni C, Gori A, Parravicini C, d'Arminio Monforte A, and Galli M.** High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma
AIDS. 1996;10:181-185. (IF: 6.881 – Cites: 25)
- 240. Meroni L, Trabattoni D, Balotta C, Riva C, Gori A, Moroni M, Villa ML, Clerici M, and Galli M.** Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection.
AIDS. 1996;10:23-30. (IF: 6.881 – Cites: 54)
- 241. Gori A, Franzetti F, Corbellino M, Degl'Innocenti M, Grassini A, Antinori S, and Moroni M.** Rapid detection of *Mycobacterium tuberculosis* in clinical specimens from HIV seropositive patients by DNA amplification.
CHEST. 1995;108:99S. (IF: 4.008 – Cites: 3)
- 242. d'Arminio Monforte A, Vago L, Cinque P, Rocca A, Novati R, Gervasoni C, Moscatelli GC, Gori A, Moroni M.** Comparison between histological diagnosis and PCR on cerebrospinal fluid in HIV-positive patients with focal intracranial lesions.
Giorn It Mal Inf. 1995;1:285-288.
- 243. Meroni L, Trabattoni D, Balotta C, Riva C, Gori A, Moroni M, Villa ML, Clerici M, and Galli M.** Type 2 cytokine profile and T lymphocyte activation in recently seroconverted HIV-1 infected subjects.
AIDS Res Hum Retroviruses. 1995;11:148S. (IF: 2.523)
- 244. d'Arminio Monforte A, Gori A, Vago L, Franzetti F, Antinori S, Moroni M, and Esposito R.** Atypical mycobacterial disease findings at autopsy in a cohort of 350 AIDS patients in Milan.
J Infect Dis. 1995;172:901. (IF: 4.910 – Cites: 3)
- 245. Gori A, Caredda F, Franzetti F, Ridolfo AL, Rusconi S.** Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a.
Lancet. 1995;345:1438-1439. (IF: 23.407 – Cites: 16)
- 246. Angarano G, Carbonara D, Costa D, Gori A, and the Italian tuberculosis drug resistance study group.** Drug resistance of *Mycobacterium tuberculosis* strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study.
Microbiologica. 1995;18:69-72. (IF: 1.00 – Cites: 8)
- 247. Antinori S, Esposito R, Gori A, Mainini F, Ridolfo AL, Rossi MC, Galimberti L, d'Arminio Monforte A, Negri C, Moroni M.** Aspetti clinici attuali della tubercolosi nei pazienti con infezione da HIV.
Giorn It Mal Inf. 1995;1:99-106.

- 248.** Morandi E, Tagliabue L, Tacchini L, Isidoro C, Buzzi G, **Gori A**, Rovati V. La valutazione delle catepsine B e D nel paziente con malattia da HIV.
GIAIDS. 1994;5:157-158.
- 249.** Franzetti F, Mena M., **Gori A**, Romaniello A, Cernuschi M, Grassini A, Degli Innocenti M.. Infezioni pneumococciche in corso di infezione da HIV.
GIAIDS. 1994;5:153-155.
- 250.** Moroni M, **Gori A**, Rusconi S, Franzetti F, Antinori S. Mycobacterial infections in AIDS: an overview of epidemiology, clinical manifestations, therapy and prophylaxis.
Monaldi Arch Chest Dis. 1994;49:432-438. (IF: 0.55)
- 251.** Tambussi G, Albarello V, **Gori A**, Bisson C, and Lazzarin A. Transitory expansion of CD3+, TCR gamma-delta+, CD16+ lymphocytic population in two patients with Human Immunodeficiency Virus (HIV) Infection in a late stage, with high levels of Natural Killer activity.
AIDS Res Human Retroviruses. 1994;10:711-715. (IF: 2.523 – Cites: 3)
- 252.** Hermans P, **Gori A**, Lemone M, Franchioly P, and Clumeck N. Possible role of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on the growth of AIDS related Kaposi's Sarcoma lesions in vivo.
Br J Hematol. 1994;87:413-14. (IF: 4.080 – Cites: 22)
- 253.** Moroni M., **Gori A**, Rusconi S, Franzetti F, Degli innocenti M, Grassini A. Le infezioni da MAC: Profilassi.
Giorn It Chemioter. 1993;40:273-276.
- 254.** d'Arminio Monforte A, Franzetti F, Bini T, **Gori A**, Gervasoni C, Mena M. Zanchetta , Moroni M. Clinical event in ddI treated patients: relation with baseline CD4+ cell count.
AIDS. 1992;6:29S. (IF: 6.881)
- 255.** d'Arminio Monforte A, Franzetti F, **Gori A**, Galimberti L, Accordini A, Moroni M. Difficult Diagnosis Fever in positive HIV Patients: Diagnostic Approach.
Giorn Mal Inf e Trop. 1991;43:660-5.
- 256.** Galli M, **Gori A**, Lupo A, Ridolfo AL, Corbellino M, Balotta C, Vago L, Vago T, Bevilacqua M, Castelli L, Baldi G, Chebat E, Mosca L, Norbiato G., and Moroni M. Cutaneous melanosis, hypotension and hyponatremia associated with hypercortisolemia, glucocorticoid resistance and high levels of alfa-interferon in AIDS patients.
AIDS Res Human Retroviruses. 1991;7:74S. (IF: 2.78)
- 257.** Tambussi G, Ridolfo AL, **Gori A**, Albarello V, Galli M, and Moroni M. Natural Killer Cytotoxic Test in the presence of Phytohemagglutinin Distinguishes between Patients in the Early and Late Stages of Human Immunodeficiency Virus Infection.
J Infect Dis. 1991;164:1027-8. (IF:4.910 – Cites: 1)